Iterum Therapeutics PLC
ITRM
Company Profile
Business description
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Contact
3 Dublin Landings
North Wall Quay
Dublin 1
DublinD01 C4E0
IRLT: +353 19038354
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
9
Stocks News & Analysis
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
stocks
Our view on oil prices after Maduro is deposed
We’ve revisited our oil price assumptions after the news from Venezuela.
stocks
Nvidia: Full steam ahead with an impressive array of announcements at CES 2026
Our view of Nvidia at the current share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.20 | 5.30 | -0.06% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,462.08 | 484.90 | 0.99% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,447.90 | 262.55 | -0.98% |
| NASDAQ | 23,547.17 | 151.35 | 0.65% |
| Nikkei 225 | 52,199.88 | 318.20 | -0.61% |
| NZX 50 Index | 13,698.98 | 35.40 | 0.26% |
| S&P 500 | 6,944.82 | 42.77 | 0.62% |
| S&P/ASX 200 | 8,714.80 | 8.70 | -0.10% |
| SSE Composite Index | 4,095.54 | 11.88 | 0.29% |